ANAyako Nakashoji

Ayako Nakashoji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ayako Nakashoji has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer

    by Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Chie Kikutake, Hiroki Ozawa, Keisuke Shigeta, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Mikita Suyama, et al.

    Resistance of NSCLCs to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is mediated by pleotropic mechanisms that pose a significant challenge for subsequent treatment. We report that the oncogenic MUC1-C/M1C protein confers resistance to osimertinib by regulating the STAT1 and interferon (IFN) type I/II pathways. Studies of osimertinib-resistant NSCLC cell lines selected for growth in the absence of drug demonstrate dependence on MUC1-C and the STAT1 pathway for memory of the refractory phenotype. This inflammatory memory of TKI resistance is mediated through activation of the MUC1 gene at (i) a proximal enhancer-like signature 1 (pELS-1) by MUC1-C and STAT1 and (ii) a pELS-2 by MUC1-C, JUN/AP-1, and PBAF. Our results further reveal that the MUC1-C-driven STAT1 inflammatory response promotes resistance of patient-derived (i) EGFR mutant NSCLC cells with MET amplification to the combination of osimertinib+MET TKIs, and (ii) EGFR(T790M/C797S) NSCLC cells to the 4th generation EGFR TKI TQB3804. Of clinical significance, we report that NSCLC cells dependent on MUC1-C for TKI resistance are druggable with an antibody-drug conjugate (M1C ADC) in vitro and in a PDX tumor model. These findings demonstrate that MUC1-C (i) is essential for TKI resistance of NSCLC cells by driving an inflammatory memory response and (ii) is a target for M1C ADC treatment of TKI-refractory NSCLCs.


  • Open Access

    Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells

    by Naoki Haratake, Shinkichi Takamori, Hideko Isozaki, Keisuke Shigeta, Chie Kikutake, Hiroki Ozawa, Atrayee Bhattacharya, Ayako Nakashoji, Mikita Suyama, Tomoyoshi Takenaka, et al.

    The APOBEC3 (A3) genes encoding cytidine deaminases evolved in mammals to restrict retroviral replication. The MUC1 gene appeared in mammals to protect barrier tissues from viral infections. There is no known involvement of the MUC1 encoded MUC1-C/M1C protein in the regulation of A3s. We found that induction of MUC1-C in NSCLC cells treated with EGFR inhibitors integrates activation of an inflammatory memory response with the type I interferon (IFN) STAT1/STAT2/IRF9 (U-ISGF3) pathway. In turn, MUC1-C drives expression of A3 genes by activating their U-ISGF3-stimulated response elements (ISREs). We also report that MUC1-C-mediated induction of type II IFN STAT1 homodimer (U-GAF) complexes and the gamma-associated signaling (GAS) pathway drives human endogenous retrovirus HERV-K102/K108 expression. Our results in NSCLC cell line and patient-derived models further demonstrate that MUC1-C activates A3 and HERV-K expression by a common MUC1-C→STAT1 auto-inductive pathway. These previously unrecognized findings demonstrate that a MUC1-C-driven inflammatory pathway coordinates activation of APOBEC3 and HERV-K expression.


  • Open Access

    MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy

    by Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori, et al.

    Androgen receptor–positive prostate cancer (PC), castration-resistant prostate cancer (CRPC), and neuroendocrine prostate cancer (NEPC) invariably become resistant to treatment with targeted and cytotoxic agents. Multiple pathways have been identified as being responsible for these pleiotropic mechanisms of resistance. The mucin 1 ( MUC1 ) gene is aberrantly expressed in CRPC/NEPC in association with poor clinical outcomes; however, it is not known if the oncogenic MUC1-C/M1C protein drives treatment resistance. We demonstrated that MUC1-C is necessary for resistance of (i) PC cells to enzalutamide (ENZ) and (ii) CRPC and NEPC cells to docetaxel (DTX). Our results showed that MUC1-C–mediated resistance is conferred by upregulation of aerobic glycolysis and suppression of reactive oxygen species necessary for self-renewal. Dependence of these resistant phenotypes on MUC1-C for the cancer stem cell (CSC) state identified a potential target for treatment. In this regard, we further demonstrated that targeting MUC1-C with an M1C antibody-drug conjugate (ADC) is highly effective in suppressing (i) self-renewal of drug-resistant CRPC/NEPC CSCs and (ii) growth of treatment-emergent NEPC tumor xenografts derived from drug-resistant cells and a patient with refractory disease. These findings uncovered a common MUC1-C–dependent pathway in treatment-resistant CRPC/NEPC progression and identified MUC1-C as a target for their therapy with an M1C ADC.


  • Open Access

    MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer

    by Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Keisuke Shigeta, Atsushi Fushimi, Kazumasa Fukuda, Yohei Masugi, et al.

    Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There is no known involvement of MUC1-C in pNET progression. The present work was performed to determine if MUC1-C represents a potential target for advancing pNET treatment. We demonstrate that the MUC1 gene is upregulated in primary pNETs that progress with metastatic disease. In pNET cells, MUC1-C drives E2F- and MYC-signaling pathways necessary for survival. Targeting MUC1-C genetically and pharmacologically also inhibits self-renewal capacity and tumorigenicity. Studies of primary pNET tissues further demonstrate that MUC1-C expression is associated with (i) an advanced NET grade and pathological stage, (ii) metastatic disease, and (iii) decreased disease-free survival. These findings demonstrate that MUC1-C is necessary for pNET progression and is a novel target for treating these rare cancers with anti-MUC1-C agents under clinical development.


  • Open Access

    Figure S4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    Regulation of ∆Np63 expression in HSC3 cells.

  • Open Access

    Data from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCC). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCC). Studies of HNSCC cell lines demonstrate that the MUC1-C subunit regulates expression of (i) RIG-I and MDA5 pattern recognition receptors, (ii) STAT1 and IFN regulatory factors, and (iii) downstream IFN-stimulated genes. MUC1-C integrates chronic activation of the STAT1 inflammatory pathway with induction of the ∆Np63 and SOX2 genes that are aberrantly expressed in HNSCCs. In extending those dependencies, we demonstrate that MUC1-C is necessary for NOTCH3 expression, self-renewal capacity, and tumorigenicity. The findings that MUC1 associates with ∆Np63, SOX2 and NOTCH3 expression by single-cell RNA sequencing analysis further indicate that MUC1-C drives the HNSCC stem cell state and is a target for suppressing HNSCC progression.Significance:This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC treatment.

  • Open Access

    FIGURE 5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    MUC1-C/STAT1 signaling regulates activation of the SOX2 gene. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). B, CAL27/CshRNA and CAL27/STAT1shRNA cells were analyzed for SOX2 gene transcription (left) and mRNA (right) levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1). C, Schema of the SOX2 gene with highlighting localization of the PLS region that contains STAT1 binding motifs. D, Soluble chromatin from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MUC1-C and anti-STAT1. The DNA samples were amplified by qPCR with primers for the SOX2 PLS region. The results (mean ± SD of three determinations) are expressed as percentage of input DNA for each sample. E, Lysates from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F, Lysates from CAL27/CshRNA and CAL27/STAT1shRNA cells were immunoblotted with antibodies against the indicated proteins.

  • Open Access

    FIGURE 6 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    MUC1-C regulates NOTCH3 expression and HNSCC cell self-renewal capacity. A, CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for NOTCH3 mRNA levels. The results (mean ± SD of four determinations) are expressed as relative levels compared with that obtained for vehicle-treated cells (assigned a value of 1; left). Lysates were immunoblotted with antibodies against the indicated proteins (right). B, GSEA of RNA-seq data from CAL27/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days using the REACTOME SIGNALING BY NOTCH3 gene signature. C, The indicated CAL27 cells treated with vehicle or DOX for 7 days were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for vehicle-treated cells (assigned a value of 1). D, Lysates from CAL27 cells treated with vehicle or 5 µmol/L GO-203 for 3 days were immunoblotted with antibodies against the indicated proteins. E, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for colony formation. Shown are representative photomicrographs of stained colonies (left). The results (mean ± SD of three determinations) are expressed as relative colony formation compared with that for vehicle-treated cells (assigned a value of 1; right). F, CAL27 cells were treated with vehicle or 5 µmol/L GO-203 while they were analyzed for tumorsphere formation. Shown are representative images of the tumorspheres (bar represents 100 µm). SFE is expressed as the mean ± SD of three independent replicates relative to that obtained for untreated cells (assigned a value of 1). G and H, Six-week-old nude mice were injected subcutaneously in the flank with 1 × 107 CAL27 cells. Mice pair-matched into groups of 5 mice each when tumors reached 100–150 mm3 were treated with vehicle control or GO-203 for the indicated days. Tumor volumes are expressed as the mean ± SEM for 5 mice (G). Lysates from control and GO-203–treated tumors were immunoblotted with antibodies against the indicated proteins (H).

  • Open Access

    Figure S3 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    Effects of targeting MUC1-C on effectors of the type I and II IFN pathways.

  • Open Access

    Figure S1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

    by Ayako Nakashoji, Naoki Haratake, Atrayee Bhattacharya, Weipu Mao, Kangjie Xu, Keyi Wang, Tatsuaki Daimon, Hiroki Ozawa, Keisuke Shigeta, Atsushi Fushimi, et al.

    Effects of silencing MUC1-C on HNSCC cell clonogenic survival.